跳至主要内容
临床试验/NL-OMON55393
NL-OMON55393已完成4 期

A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL TRIAL ON HOME PARENTERAL NUTRITION USING AN OMEGA-3 FATTY ACID ENRICHED MCT/LCT LIPID EMULSION - The HOME Study (HPN WITH OMEGA-3)

B.Braun Melsungen AG0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Signed informed consent available
  • 2. Male or female patients >= 18 years of age
  • 3. Patients with chronic intestinal failure receiving HPN including lipids in
  • the parenteral macronutrients have not been changed by more than 10% for
  • at least 3 months
  • 4. Patients receiving >= 3.0 g lipids/kg body weight per week

排除标准

  • 1. Persistent high total bilirubin values in medical history of the last 6
  • (> 40µmol/l)
  • 2. Patients in whom PN was interrupted for longer than 4 continuous weeks in
  • the preceding 6 months
  • 3. Patients with history of cancer and anti-cancer treatment within the last
  • 4. Hypersensitivity to egg, fish or soya-bean protein or to any of the active
  • substances or excipients
  • 5. Patients treated in the past or currently with Teduglutide
  • 6. Contraindications to investigational products (if available from medical
  • records) including:
  • - Severe hyperlipidemia, including severe hypertriglyceridaemia (>= 1000
  • mg/dl or 11.4 mmol/l)
  • - Severe coagulopathy
  • - Intrahepatic cholestasis
  • - Severe hepatic insufficiency
  • - Severe renal insufficiency in absence of renal replacement therapy
  • - Acute thromboembolic events
  • - Fat embolism
  • - Aggravating haemorrhagic diatheses
  • - Metabolic acidosis
  • 7. General contraindications to parenteral nutrition (if available from medical
  • records) including:
  • - Unstable circulatory status with vital threat (states of collapse and shock)
  • - Acute phase of cardiac infarction or stroke
  • - Unstable metabolic conditions (e.g. decompensated diabetes mellitus,
  • severe sepsis, coma of unknown origin)
  • - Inadequate cellular oxygen supply
  • - Disturbances of the electrolyte and fluid balance (e.g. hypokalaemia and
  • hypotonic dehydration)
  • - Acute pulmonary edema
  • - Decompensated cardiac insufficiency
  • 8. Positive test for HIV, Hepatitis B or C (from medical history)
  • 9. Known or suspected drug or alcohol abuse
  • 10. Patients who are unwilling or mentally and/or physically unable to adhere to
  • study procedures
  • 11. Participation in another interventional clinical trial in parallel or
  • within three
  • months prior to the start of this clinical trial
  • 12. Any medical condition that in the opinion of the investigator might put the
  • subject at risk or interfere with patients participation
  • For women with childbearing potential (i.e. females who are not chemically or
  • surgically sterile or females who are not post-menopausal)
  • 13. Women of childbearing potential tested positive on standard pregnancy test
  • (urine dipstick)
  • 14. Lactation
  • 15. Women of childbearing potential who do not agree to apply adequate
  • contraception

研究者

相似试验

进行中(未招募)
1 期
Clinical trial to investigate safety and efficacy of an Omega-3-fatty acid triglycerides (fish-oil”) enriched lipid emulsion in comparison to a lipid emulsion not containing fish-oil” in home parenteral nutrition in adults
EUCTR2015-000849-23-NLB. Braun Melsungen AG160
进行中(未招募)
1 期
Clinical trial to investigate safety and efficacy of an Omega-3-fatty acid triglycerides (fish-oil”) enriched lipid emulsion in comparison to a lipid emulsion not containing fish-oil” in home parenteral nutrition in adultsChronic intestinal failureMedDRA version: 20.0 Level: SOC Classification code 10017947 Term: Gastrointestinal disorders System Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2015-000849-23-GBB. Braun Melsungen AG160
未知
不适用
A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER, PHASE 2 STUDY OF THE SAFETY/ TOLERABILITY AND EFFICACY OF JNJ-32729463 COMPARED WITH MOXIFLOXACIN FOR THE TREATMENT OF SUBJECTS REQUIRING HOSPITALIZATION FOR COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) WITH A PORT SCORE OF II OR GREATER
PER-035-11FURIEX PHARMACEUTICALS, INC,
进行中(未招募)
不适用
A CONTROLLED, RANDOMISED, DOUBLE-BLIND, MULTICENTER STUDY, COMPARING METHOTREXATE VS PLACEBO IN CORTICOSTEROID-DEPENDENT ULCERATIVE COLITIS - METEORSteroid-dependent ulcerative colitis
EUCTR2006-003607-40-BEBesancon University Hospital110
进行中(未招募)
不适用
A CONTROLLED, RANDOMISED, DOUBLE-BLIND, MULTICENTER STUDY, COMPARING METHOTREXATE VS PLACEBO IN STEROID-REFRACTORY ULCERATIVE COLITIS - METEOR
EUCTR2006-003607-40-NLBesancon University Hospital110